CMPS Latest Headlines

LifeSci Capital Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

at www.tipranks.com (Sat, 25-Apr 3:55 PM)

Trending stocks this week as markets weigh war risks and corporate results

at seekingalpha.com (Sat, 25-Apr 1:17 PM)

COMPASS Pathways psilocybin asset for depression awarded Commissioner voucher

at seekingalpha.com (Fri, 24-Apr 10:54 AM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopar Therapeutics Inc (MNPR)

at www.tipranks.com (Tue, 21-Apr 7:00 AM)

Compass Pathways Rises on White House Support and Strong Phase 3 Data for Psychedelic Treatment

Market Chameleon (Mon, 20-Apr 9:54 AM)

Compass Pathways Highlights Regulatory Progress with Needham Forum Appearance—What’s Next for Psychedelic Mental Health Treatment?

Market Chameleon (Mon, 20-Apr 7:05 AM)

Compass Pathways Launches U.S. Grant Program to Elevate Provider Training Ahead of Potential COMP360 Approval

Market Chameleon (Tue, 14-Apr 7:31 AM)

Compass Pathways Signals Confidence with Stifel CNS Forum Appearance as COMP360 Gains Regulatory Momentum

Market Chameleon (Thu, 12-Mar 9:01 AM)

CMPS Raises $200 Million from Warrant Exercises—Extends Cash Runway Through 2028, Boosts Funding for COMP360 Trials

Market Chameleon (Thu, 26-Feb 7:45 AM)

Compass Pathways Secures $150 Million to Advance Late-Stage Trials—What’s the Strategic Impact?

Market Chameleon (Thu, 19-Feb 7:11 AM)

Compass Pathways Announces $150 Million Public Offering: What This Means for the Company's Next Steps

Market Chameleon (Wed, 18-Feb 10:34 AM)

Compass Pathways Sets Stage for Key Phase 3 Data Reveal Amid Surging Investor Interest

Market Chameleon (Tue, 17-Feb 9:55 AM)

Phase 3 COMP360 Trial Achieves Key Depression Endpoint—Rapid and Durable Efficacy for Treatment-Resistant Patients

Market Chameleon (Tue, 17-Feb 7:05 AM)